PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
35.97%
Net income growth above 1.5x AVXL's 7.13%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Deferred tax of 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-6.03%
Negative yoy SBC while AVXL is 24.01%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-150.99%
Negative yoy working capital usage while AVXL is 289.44%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-123.01%
Both negative yoy AP, with AVXL at -118.65%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-179.37%
Negative yoy usage while AVXL is 988.70%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-42.60%
Both negative yoy, with AVXL at -92.03%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-14.43%
Negative yoy CFO while AVXL is 54.38%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy issuance while AVXL is 57819525.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.